The United Kingdom and the United States have forged a important commercial pact that will keep zero import taxes on British drug shipments entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these crucial products will stay at zero for a period of 36 months.
This deal is in response to earlier threats to significantly raise import taxes on branded drug products, with increases discussed as high as 100%.
"This deal between the UK reinforces the worldwide climate for new treatments and establishes long-overdue balance to American-British pharmaceutical trade," an announcement noted.
Economic Importance
Pharmaceuticals constitute one of the UK's most significant export categories to the America, which is by far the primary destination for leading British pharmaceutical firms.
Statistics show that in the 12 months prior to last September, the UK exported medicines worth billions to the US. This amount accounted for a significant portion of British export trade in that span.
"This agreement secures employment, increases capital expenditure and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact entails several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to raise total public funding on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be limited at 15%. In the past, refunds topped twenty percent.
Recent Tensions
This agreement follows a ongoing row between the drug companies and the British authorities over spending levels and approval rates.
This friction were exacerbated by arguments that US customers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been directed toward projects in the United States.
A senior figure acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the past decade.
